VivoSeq
Other

PET/CT

0

Pipeline Programs↗

17

Active Trials↗

2

Companies Involved↗

PET/CT is an early-stage landscape with 0 programs across 2 companies. The most active players are Yantai LNC Biotechnology Singapore PTE. LTD., The European Uro-Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Y

Yantai LNC Biotechnology Singapore PTE. LTD.

0 programs

PreclinicalT

The European Uro-Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

40

clinical trials

Recruiting11 · 28%
Unknown status11 · 28%
Completed11 · 28%
Active, not recruiting4 · 10%
Not yet recruiting2 · 5%
Terminated1 · 3%

Clinical Trials

Trial Activity

40 trials

Al18F-NOTA-LM3 PET/CT in Patients With TIO
Recruiting·PPeking Union Medical College Hospital·N/A·NCT07366099·40 enrolled
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
Recruiting·FFirst Affiliated Hospital of Fujian Medical University·Phase 1·NCT06612580·10 enrolled
68Ga-AAZTA-093 PET/CT: First-in-human Study
Recruiting·FFirst Affiliated Hospital of Fujian Medical University·Phase 1·NCT06437496·30 enrolled
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT
Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT06222489·16 enrolled
68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies
Recruiting·FFirst Affiliated Hospital of Fujian Medical University·Phase 1·NCT06438250·5 enrolled
Lung Nodule Detection Using Ultra-long FOV PET/CT
Recruiting·UUniversity Medical Center Groningen·Phase 4·NCT05463913·20 enrolled
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Recruiting·PPeking Union Medical College Hospital·Phase 1·NCT05069220·150 enrolled
18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study
Recruiting·FFirst Affiliated Hospital of Fujian Medical University·Phase 1·NCT06734572·5 enrolled
68Ga-NI-FAPI PET/CT: First-in-human Study
Recruiting·FFirst Affiliated Hospital of Fujian Medical University·Phase 1·NCT06688305·40 enrolled
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study
Recruiting·FFirst Affiliated Hospital of Fujian Medical University·Phase 1·NCT06688188·5 enrolled
Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Small Cell Lung Cancer
Recruiting·TThe First Affiliated Hospital of Xiamen University·Preclinical·NCT07677787·20 enrolled
Study of Radiotracer [18F]Fluortriopride ([18F]FTP) by PET/CT
Active, not recruiting·UUniversity of Pennsylvania·Phase 1·NCT02379338·29 enrolled
POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions
Active, not recruiting·UUniversity of Florida·Phase 2·NCT07220720·30 enrolled
Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT
Active, not recruiting·UUniversity of Pennsylvania·Phase 1/2·NCT02815917·30 enrolled
Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors
Active, not recruiting·FFirst Hospital of China Medical University·Phase 1/2·NCT07059832·30 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)